rawfin.tv
Solid Biosciences' SGT-003 Gains EU Orphan Drug Designation
RegulationstocksAI Generated

Solid Biosciences' SGT-003 Gains EU Orphan Drug Designation

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Solid Biosciences Inc. (SLDB) has been granted orphan drug designation by the European Commission for SGT-003. This designation supports the development of therapies for rare diseases, potentially accelerating the drug's path to market.

SLDBorphan-drugbiotechnologyEU-regulationdrug-development

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks